Immunic, Inc (NASDAQ:IMUX) announced it strengthened its leadership team on Wednesday as the company prepares to advance its multiple sclerosis pipeline through late-stage development and potential commercialization.

Immunic Appoints Erik Lundgren As CEO

Immunic named biopharmaceutical executive Erik Lundgren as CEO effective May 22, 2026, with his employment beginning June 1.

Lundgren succeeds Daniel Vitt, Ph.D., who will continue overseeing scientific strategy and portfolio advancement while remaining on Immunic's board of directors.

Company Advances Late-Stage Multiple Sclerosis Programs

Immunic said Lundgren will lead the company as it advances vidofludimus calcium through late-stage clinical development, including the pivotal phase 3 ENSURE program in relapsing multiple sclerosis and a planned phase 3 program in primary progressive multiple sclerosis.

The company is also preparing for potential regulatory filings, approval efforts, and commercialization activities.

Lundgren Brings Deep Genentech And MS Experience

Lundgren joins Immunic with nearly two decades of experience spanning commercial strategy, marketing, product launches, portfolio leadership, and general management, particularly in multiple sclerosis.

He most recently served as senior vice president of the Commercial Portfolio Organization at Genentech, part of Roche Group (OTC:RHHBY), after previously leading Roche Czech Republic as general manager.

Earlier in his career, he supported the launch and commercialization of Ocrevus, a major treatment for RMS and PPMS, and also worked on oncology products including Kadcyla and Zelboraf.

Immunic's compensation committee granted Lundgren an equity option to purchase 1 million shares under the company's 2026 inducement equity compensation plan.

IMUX Price Action: Immunic shares were up 1.32% at $13.14 during premarket trading on Wednesday, according to Benzinga Pro data.